Pending postmarket study commitments dropping

The FDA says 71% (899) of pending postmarketing study commitments promised by drug sponsors at the time of approval have never been started. This is a worsening trend; in 2005, 65% (797) of pending studies had not been started.

You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.